Mast cells have been implicated in the pathogenesis of the matrix degradation observed in the cartilaginous and osseous structures of the rheumatoid joint. We previously reported that human mast cell tryptase, a 134-kD granule-associated neutral protease, is present in rheumatoid synovium and can activate collagenase in crude culture medium in vitro. The present study attempts to depict the precise mechanism of this activation. To express full activation of latent collagenase, matrix metalloproteinase 3 (MMP-3) or stromelysin, can be activated by tryptase in a time and dose-dependent manner. Tryptase was not capable of generating active collagenase in the crude media from cultured rheumatoid synoviocytes depleted of proMMP-3 by immunoadsorption. In addition, the function of the tissue inhibitor of metalloproteinases (TIMP) was not altered by tryptase, and SDS-PAGE analysis revealed no degradation of TIMP by tryptase. The tryptase dependent activation of synoviocyte procollagenase thereby appears to be entirely dependent upon its ability to activate proMMP-3.
Introduction
Recent evidence suggests that a family of latent metalloproteinases may be elaborated by synovial adherent cells and, collectively these enzymes have the ability to degrade all the components of human extracellular matrix (1) (2) (3) (4) (5) (6) . The activation of latent collagenase (MMP-l)l likely involves an enzymatic cascade that is dependent upon activation of the zymogen of MMP-3 (proMMP-3), which in turn, activates latent collagenase (7, 13) . Once activated, MMP-3 additionally can degrade proteoglycans, fibronectin, laminin, type IV and type IX collagen, and gelatin (1, 4, 5) . The activation of proMMP-3 is therefore an important step in the initiation of matrix degra- 1 . Abbreviations used in this paper: APMA, aminophenyl mercuric acetate; CM, conditioned media; DFP, diisopropylfluorophosphate; MMP-3, matrix metalloproteinase 3; proMMP-3, zymogen activation of MMP-3; TAME, tosyl-L-arginine methyl ester; TIMP, tissue inhibitor metalloproteinase. dation, and is likely the rate limiting step in collagenolysis (7, 13) .
In vitro activation of proMMP-3 is attained with the addition of trypsin-like proteases or organomercurials (4, 7, 14) , but the activator in situ is unknown. Since mast cells accumulate in rheumatoid synovium and appear to be particularly prevalent near sites of cartilage erosion (15) , we tested the hypothesis that these cells secreted a protease capable of initiating the collagenolytic process. Tryptase is a 1 34-kD neutral protease selectively synthesized by mast cells (and in trace amounts by basophils) and comprising > 25% of the dry weight of these cells (16, 17) . We and others have been unable to detect any specific matrix substance that is susceptible to degradation directly by tryptase ( 1 8).2 However, we previously reported that tryptase, when added to synoviocyte conditioned culture media, generated active collagenase (19) . The precise pathway through which this activation proceeded was not elucidated. In this study we utilized purified reagents and specific antisera to more precisely define the mechanism of procollagenase activation to further explore the potential role of mast cells in matrix degradation. Methods Materials. Bacterial collagenase (Clostridia type II), hyaluronidase, trypsin, deoxyribonuclease, transferrin (human), diisopropylfluorophosphate (DFP), and soybean trypsin inhibitor were purchased from Sigma Chemical Co. (St. Louis, MO) and heparin from Gibco Laboratories (Grand Island, NY). Tryptase was purified to apparent homogeneity from dispersed human lung mast cells as described previously (17) . Heparin (10 yg/ml) was added to all assays in which tryptase was used (19) . ProMMP-3 was purified from human rheumatoid synovial cells stimulated by rabbit macrophage conditioned culture medium as described previously (13) . Briefly, this involved applying -40 ml of culture media to an affinity column of monospecific sheep anti-(human MMP-3) IgG coupled to Affi-Gel 10 (Bio-Rad) and eluting with 6 M urea in 50 mM Tris-HCl, pH 7.5. The culture media in the effluent contained no detectable proMMP-3 activity, even after 4-aminophenylmercuric acetate (APMA). This was further confirmed by immunoblotting analysis. The culture medium depleted from proMMP-3 was stored at -20°C for use in certain experiments.
Synovial latent collagenase was studied in both crude and partially purified forms after release into media by stimulated rheumatoid synoviocytes (19 Gel electrophoresis and immunoblots. SDS/PAGE (10% total acrylamide) was performed under reducing conditions (20 mM DTT) using standard techniques and the proteins stained with Coomassie brilliant blue R-250 (24) . To analyze the molecular weight changes of proMMP-3 upon tryptase treatment, the samples were applied to one dimensional electrophoresis, and the proteins were electro-transferred (25) overnight to nitrocellulose paper (Hoefer Scientific Instruments, San Francisco, CA), followed by a 2-h incubation with sheep antihuman MMP-3 at a dilution of 1:2,000. Bound antibodies were detected, by complexing with alkaline-phosphatase conjugated rabbit anti-sheep antibody at 1:500 dilution (Kirkegarrd-Perry, Gaithersburg, MD), and visualizing with the substrate nitroblue tetrazolium, as described by Blake et al. (26) .
Inhibition studies. To study the effects of tryptase on the metalloproteinase-TIMP complex, either partially purified synovial procollagenase activated with APMA (1.5 mM at 24°C for 30 min) or purified MMP-3 was incubated with increasing amounts of TIMP. After a 30-min incubation at 37°C in 50 mM Tris-HCI buffer, pH 7.4, an aliquot was removed and treated with tryptase at varying concentrations. The activity of collagenase or MMP-3 was then determined. In separate experiments, TIMP was initially treated with tryptase (1.0 gg/ml at 37°C for 30 min) and then added to the media containing APMA-activated collagenase or MMP-3 to determine whether the inhibitory capacity of TIMP was altered after tryptase treatment.
treatment with APMA for 12 h. Tryptase alone had no degradative activity when incubated directly with the MMP-3 sub-
Western blot-analysis of tryptase-activated MMP-3. Purified proMMP-3 and the tryptase-activated MMP-3 were subjected to SDS-PAGE under reducing conditions and analyzed by immunoblotting using monospecific antisera to MMP-3.
As shown in Fig. 2 , a sequential processing of proMMP-3 by 25 nM tryptase (3.3 Ag/ml) occurred over 18 h. An intermediate proMMP-3 product of 49 kD was seen after a 30-min incubation with tryptase, which was then converted to a 45-kD species after 120 min. This molecular weight conversion is complete after an 18-h incubation. Maximal activity of MMP-3 is observed after 2 h and is comparable to that attained with a-chymotrypsin and APMA. No diminution of MMP-3 activity was observed after 18 h. Activation of latent collagenase. Crude media containing latent collagenase was treated with trypsin, APMA, and tryptase. DFP was added to inactivate tryptase and trypsin after activation of the media and before the exposure to the collagenase assay. As shown in Table I all ofthese treatments ofthe crude culture medium activated procollagenase. However, after exhaustive immunoadsorption of the media to remove proMMP-3 (CM-proMMP-3), the tryptase was incapable of activating the crude media even after 60 min (Table I) . Consistent with previous experiments, tryptase itself showed negligible collagenase activity directly (data not shown). Hence, tryptase activation of synovial procollagenase appears dependent upon the presence of MMP-3.
This observation is further confirmed by examining the digestion of collagen with SDS-PAGE, using tryptase-activated crude conditioned media (CM) before and after immunoadsorption ofproMMP-3. As shown in Fig. 3 , interstitial collagen is degraded at room temperature after 14 h by synoviocyte Results Activation ofproMMP-3. Purified proMMP-3 was activated by tryptase in a concentration-dependent fashion after 30 min at 37°C. The maximal activity ofMMP-3 was accomplished with 20 nM tryptase (27 ug/ml), comparable to that seen with 35 nM (1 ,ug/ml) of a known activator a-chymotrypsin (Fig. 1) culture media, which was activated by either APMA or tryptase only if proMMP-3 was present in the media. Effect of tryptase on tissue inhibitor. The possibility that tryptase might interact with the enzyme-inhibitor complex to yield free enzyme and inactivate inhibitor was investigated.
Recombinant TIMP (10 gtM) was allowed to incubate with synoviocyte crude media which was previously activated by trypsin (10 ,gg/ml for 30 min). As shown in Table II , tryptase (40 nM) had no functional effect on the inactive collagenase-TIMP complex after 30 min incubation. Furthermore, if tryptase (40 nM) was allowed to incubate with TIMP initially for 30 min and the inhibitor was subsequently added to active collagenase, no significant loss of inhibitory activity was ob- and then subsequently exposed to tryptase (40 nM).
served (Table II) . To investigate the possibility that TIMP exposed to tryptase might result in a partial loss of inhibitory capacity not revealed when TIMP was tested in excess concentrations relative to collagenase, decreasing amounts of TIMP were examined before and after tryptase exposure. As shown in Fig. 4 , no significant effect was seen after TIMP was exposed to tryptase in its ability to inhibit collagenase regardless of the stoichiometric relationship between TIMP and collagenase.
Varying concentrations of native TIMP (0.36-360 nM) added to active MMP-3 (10-'-103 nM) yielded the expected concentration-related inhibition (Fig. 5) . Even when TIMP was treated with tryptase (60 nM for 1 h) stabilized with heparin or heparin alone, a similar stoichiometric inhibition for MMP-3 was obtained (Fig. 5) analyzed by SDS-PAGE under reducing conditions (20 mM DTT) before and after treatment with tryptase (2.5 ,ug/ml). No change could be detected after y tryptase treatment (Fig. 6 ). Therefore, tryptase had no measurable effect on the metalloproteinase inhibitor.
Discussion
Impaired extracellular regulation of metalloproteinases released by specialized synovial cells is central in the develop-I. ment of premature articular breakdown in rheumatoid arthritis (27, 28) . It appears that these latent proteinases are secreted in excess after enhanced cellular transcription and translation, under the influence of specific cytokines or other endogenous activators (29) (30) (31) . The proenzymes are then activated extracellularly and may either proceed to degrade the matrix or else complex with tissue inhibitors. In vitro, this activation occurs spontaneously or by interacting with neutral serine proteases or organomercurials (32) . The precise manner in which this occurs in situ is unknown. Plasma kallikrein has been proposed as a major activator in synovial fluid (33), but documentation of its presence at the site of cartilage erosion is lacking. However, mast cells have been noted to accumulate in clusters at the cartilage-pannus junction (15) . Furthermore, tryptase, the major neutral protease of human mast cells, can be demonstrated by immunoperoxidase techniques in rheumatoid synovium (19, 34) . Previously, we reported that synovial mast cells in vitro can be induced to release tryptase and activate latent collagenase present in crude culture media ( 19) . The mechanism in which tryptase leads to an active form of collagenase is explored in this report. The activation of procollagenase occurs after cellular release and recent evidence suggests that full activation likely involves an intermediary "proactivator" (7) (8) (9) (10) (11) (12) (13) . It has been proposed that this proactivator has in itself a broad spectra of metal-dependent matrix degrading activities and represents a member of a family of metalloproteinases, termed MMP-3 or stromelysin (4) (5) (6) 35) . Rheumatoid synoviocytes release a latent form of MMP-3 in culture and its properties after purification have been described (1, 4, 7) . Furthermore, depleting rheumatoid synoviocyte media of MMP-3 by immunoadsorption followed by activation by trypsin or APMA reduces the collagenolytic activity by over 80-90% (12, 13) .
Our results, which indicate that prompt activation of purified proMMP-3 can result from incubation with physiologic concentrations of mast cell tryptase, adds to the list of serine esterases that can lead to an active MMP-3 moiety. However, in comparison to other endopeptidases such as trypsin, kallikrein, thermolysin, or plasmin, tryptase (at the concentrations employed in this study) was capable of fully and rapidly activating MMP-3 and this activity was sustained even upon prolonged incubation with high concentrations of tryptase (14) . The active MMP-3 can then result in dissolution of proteoglycans, gelatin, type IV collagen, fibronectin, laminin and probably other matrix substances, in addition to fully activating synoviocyte procollagenase. The activation of proMMP-3 by tryptase yields a lower molecular weight species as demonstrated in this report using immunoblots. This digestion pattern is similar to that seen with activators such as trypsin, a-chymotrypsin, or APMA (14) . The active MMP-3 in synoviocyte media then converts collagenase to an active enzyme with 100% activity. However, we did observe that organomercurial or trypsin activation ofcrude synoviocyte culture media led to greater collagenase activity then with tryptase. The reason for this is not entirely clear but may relate to a complex dynamic interaction whereupon tryptase fully activates proMMP-3 but simultaneously degrades collagenase in a manner to reduce its maximal activity.3
The other possible mechanism leading to an active collagenase species is to interfere with the ability of the tissue inhibitor to counteract the activated enzyme following exposure to certain serine proteinases, as reported previously (36) . This might occur by either degrading the inhibitor upon exposure to tryptase or by dissociating the enzyme-inhibitor complex to yield free enzyme. Both of these possibilities were tested using recombinant TIMP incubated with tryptase before and after exposure to active MMP-3 or active collagenase in crude media. Under the experimental conditions employed, no significant effect of tryptase was observed.
The contribution of mast cell products in altering connective tissue metabolism remains unknown at present, but is likely to be considerable. Mast cells are prevalent in connective tissues and accumulate in chronic inflammatory conditions marked by abnormal homeostasis of connective tissue elements. This includes not only synovitis, which results in cartilage dissolution, but also in chronic periodontitis, in invasive carcinoma, and at sites of collagen excess in a number of pathologic settings (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) . Whether the cells in the latter setting are promoting scar formation or, playing a frustrated part in attempting dissolution, is unclear. Nonetheless, human mast cells are unique in their abundance of the neutral protease, tryptase. Plasma and tissue protease inhibitors appear ineffective in regulating this enzyme (16, 17) . Consequently, tryptase complexed with heparin may act locally in an uninhibited fashion. Thus mast cells, which have been observed near sites of cartilage erosion, may contribute to matrix degradation during the development ofthe rheumatoid pannus. The biochemical mechanism involves a cascade of several metalloproteinases; tryptase may serve a critical role initiating this pathological process.
